Title |
Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
|
---|---|
Published in |
Advances in Therapy, July 2014
|
DOI | 10.1007/s12325-014-0139-3 |
Pubmed ID | |
Authors |
Chiara Caresano, Guido Di Sciascio, Andrea Fagiolini, Giuseppe Maina, Giulio Perugi, Claudio Ripellino, Claudio Vampini |
Abstract |
Bipolar disorder is a chronic disease characterized by periods of mania or hypomania, depression, or a combination of both (mixed state). Because bipolar disorder is one of the leading causes of disability, it represents an important economic burden on society. Asenapine (ASE) is a new second-generation antipsychotic developed and approved for the treatment of manic or mixed episodes associated with bipolar disorder. The objective of the present study was to assess the cost-effectiveness of ASE compared to olanzapine (OLA) in the treatment of patients experiencing mixed episodes associated with bipolar I disorder in the context of the Italian National Health Service (NHS). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 25% |
Student > Ph. D. Student | 6 | 15% |
Professor | 4 | 10% |
Student > Postgraduate | 4 | 10% |
Student > Master | 4 | 10% |
Other | 5 | 13% |
Unknown | 7 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 20% |
Nursing and Health Professions | 5 | 13% |
Psychology | 5 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Neuroscience | 2 | 5% |
Other | 7 | 18% |
Unknown | 11 | 28% |